Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML

Affiliations

• ¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
• ² The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.
• ³ INSERM U1163 and CNRS 8254, Imagine Institute, Université Paris Saclay, Paris, France.
• ⁴ Bioinformatics Graduate Program, Boston University, Boston, MA, USA.
• ⁵ INSERM UMR 944, Institut Universitaire d'Hématologie, Hôpital St. Louis, Paris, France.
• ⁶ Département d'Hématologie, Hôpital Saint-Louis, Assistance Publique - Hopitaux de Paris, Paris, France.
• ⁷ Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.
• ⁸ Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Kimberly_Stegmaier@dfci.harvard.edu.
• ⁹ The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA. Kimberly_Stegmaier@dfci.harvard.edu.
• ¹⁰ INSERM UMR 944, Institut Universitaire d'Hématologie, Hôpital St. Louis, Paris, France. alexandre.puissant@inserm.fr.